Givinostat hydrochloride

• CAT Number: I002531
• CAS Number: 199657-29-9
• Molecular Formula: C24H28ClN3O4
• Molecular Weight: 457.95
• Purity: ≥95%
• Target: HDAC
• Solubility: 10 mM in DMSO
• Storage: Store at -20°C
• IC50: 10 nM (for HD2), 7.5 nM (for HD1-B), 16 nM (for HD1-A) [2]
• IUPAC Name: [6-(diethylaminomethyl)naphthalen-2-yl]methyl N-[4-(hydroxycarbamoyl)phenyl]carbamate;hydrochloride
• InChI: InChI=1S/C24H27N3O4.ClH/c1-3-27(4-2)15-17-5-7-21-14-18(6-8-20(21)13-17)16-31-24(29)25-22-11-9-19(10-12-22)23(28)26-30;/h5-14,30H,3-4,15-16H2,1-2H3,(H,25,29)(H,26,28);1H
• InChIKey: QKSGNWJOQMSBEP-UHFFFAOYSA-N
• SMILES: CCN(CC)CC1=CC2=C(C=C1)C=C(C=C2)COC(=O)NC3=CC=C(C=C3)C(=O)NO.Cl

Givinostat hydrochloride (Cat.No:I002531) is a pharmaceutical compound used in medical research and clinical trials. It belongs to the class of histone deacetylase inhibitors and has shown potential as a treatment for various diseases, including inflammatory conditions and certain types of cancers. Givinostat hydrochloride works by modulating gene expression and regulating cell signaling pathways.

Reference

[1]. Wang YG, et al. Givinostat inhibition of hepatic stellate cell proliferation and protein acetylation. World J Gastroenterol. 2015 Jul 21;21(27):8326-8339.

[2]. Leoni F, et al. The histone deacetylase inhibitor ITF2357 reduces production of pro-inflammatory cytokines in vitro and systemic inflammation in vivo. Mol Med. 2005 Jan-Dec;11(1-12):1-15.